USP announces new Vice President of Chemical Medicines

Former official of FDA’s Center for Drug Evaluation and Research to advance the development of new monographs

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

The U.S. Pharmacopeial Convention (USP) is pleased to announce the appointment of Jon Clark, M.S., as vice president of Chemical Medicines – External Development. He joined USP on October 14, 2013.

Mr. Clark brings many years of experience in the global pharmaceutical industry and over 20 years of experience with the US Food & Drug Administration (FDA). For the last 10 years at FDA, Mr. Clark has held the title of Associate Director for Program Policy, Office of Pharmaceutical Science, in FDA’s Center for Drug Evaluation and Research.

As vice president, Mr. Clark will lead the development of new monographs in both the United States Pharmacopeia-National Formulary (USP-NF) and the USP Medicines Compendium (MC), focusing on the possibility of comprehensive monographs that are potentially suitable for all three compendia. Mr. Clark will work closely with Todd Cecil, Ph.D., vice president of Chemical Medicines — Monograph Modernization to advance a full cohort of monographs.

Mr. Clark holds an M.S. in Chemistry from Rutgers University and a B.S. in Chemistry from University of Michigan Ann Arbor.

Media inquiries may be directed to [email protected].

Medical Device Innovations Report
Cutting-edge packaging technologies are transforming the medical device sector in PMMI’s “Innovation in Medical Device” report, featuring advanced materials, smart solutions, and evolving regulations. Editors share insights from nearly 300 PACK EXPO booth visits—each product deemed new and truly innovative—alongside video demonstrations of the equipment and materials on display.
Learn More
Medical Device Innovations Report
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?